The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients
H Bai, B Han - American journal of clinical oncology, 2013 - journals.lww.com
Background: Brain metastases commonly occur in non–small cell lung cancer (NSCLC), and
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor-
associated tyrosine kinase, has shown antitumor activity in advanced NSCLC. This study
evaluates erlotinib in the treatment for brain metastases from NSCLC. Patients and Methods:
We retrospectively reviewed 40 NSCLC patients with brain metastases. All were treated with
oral erlotinib and followed until disease progression, death, or intolerable side effects. EGFR …
patient prognosis is poor. Erlotinib, a specific inhibitor of epidermal growth factor receptor-
associated tyrosine kinase, has shown antitumor activity in advanced NSCLC. This study
evaluates erlotinib in the treatment for brain metastases from NSCLC. Patients and Methods:
We retrospectively reviewed 40 NSCLC patients with brain metastases. All were treated with
oral erlotinib and followed until disease progression, death, or intolerable side effects. EGFR …
以上显示的是最相近的搜索结果。 查看全部搜索结果